PLC Systems Inc. Launches New Corporate Website Including a Suite of Online Digital Corporate Communication Channels

MILFORD, MA -- (Marketwired) -- 04/29/13 -- PLC Systems Inc. (OTCQB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced the launch of a new corporate website including a suite of online digital corporate communication channels to maintain on-going direct communication with shareholders. The Company has launched official portals on various social media channels including Facebook, Twitter, LinkedIn, YouTube and Google+.

According to CEO Mark Tauscher, "We are pleased to announce the launch of our new website and social media channels. By utilizing social media channels, we are able to communicate more effectively and transparently with our shareholders, customers and the public. In addition, these portals will allow us to raise awareness of important company clinical developments and industry information. We look forward to having you follow us."

Links to the new communication tools are here:

Facebook: https://www.facebook.com/pages/PLC-Systems-Inc/596548940356222
Twitter: https://twitter.com/PLC_systems
LinkedIn Page: https://www.linkedin.com/company/plc-medical-systems?trk=hb_tab_compy_id_105544
YouTube: https://www.youtube.com/user/PLCSystemsInc
Google+: https://plus.google.com/u/0/b/104401148383596769076/104401148383596769076/posts

In using these social media portals, the Company intends to continue to fully comply with Regulation FD and recent pronouncements by the Securities and Exchange Commission by using only recognized channels of distribution such that their use will meet the requirements in Regulation FD that material information be distributed on a broad, non-exclusionary basis.

About PLC Systems Inc.

PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2012, a copy of which is on file with the SEC.

PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.

Attachment Available: http://www.marketwire.com/library/MwGo/2013/4/29/11G004787/MultimediaAsset1-1848975661.pdf

   
        
      Contacts:
      
      CAP Strategies, LLCLisa Caperelli215-340-1241 Lisa.caperelli@gmail.comPLC Systems Inc.Gregory Mann, Chief Financial Officer508-541-8800gmann@plcmed.com
      

Source: PLC Systems, Inc.